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Abstract
Background: The chaperone ClpB, a bacterial protein, is a conformational antigen-mimetic of α-melanocyte-
stimulating hormone (α-MSH) implicated in body weight regulation in mice. We here investigated the potential
associations of gut bacterial ClpB-like gene function with obesity status and gut microbiota in humans.
Results: Gut microbiota ClpB KEGG function was negatively associated with body mass index, waist circumference,
and total fat mass (DEXA). The relative abundance (RA) of several phyla and families directly associated with ClpB
was decreased in subjects with obesity. Specifically, the RA of Rikenellaceae, Clostridiaceae and not assigned
Firmicutes were lower in subjects with obesity and positively associated with gut bacterial ClpB-like gene function
(not assigned Firmicutes (r = 0.405, FDR = 2.93 × 10−2), Rikenellaceae (r = 0.217, FDR = 0.031), and Clostridiaceae (r =
0.239, FDR = 0.017)). The gut bacterial ClpB-like gene function was also linked to specific plasma metabolites
(hippuric acid and 3-indolepropionic acid) and fecal lupeol. The α-MSH-like epitope similar to that of Escherichia coli
ClpB was also identified in some sequences of those bacterial families.
After fecal transplantation from humans to mice, the families that more contributed to ClpB-like gene function in
humans were also associated with ClpB-like gene function in mice after adjusting for the donor’s body mass index
(not assigned Firmicutes (r = 0.621, p = 0.003), Prevotellaceae (r = 0.725, p = 4.1 × 10−7), Rikenellaceae (r = 0.702, p =
3.9 × 10−4), and Ruminococcaceae (r = 0.526, p = 0.014)). Clostridiaceae (r = − 0.445, p = 0.038) and Prevotellaceae RA
(r = − 0.479, p = 0.024) and were also negatively associated with weight gain in mice. The absolute abundance (AA)
of Prevotellaceae in mice was also positively associated with the gut bacterial ClpB-like gene function in mice.
DESeq2 identified species of Prevotellaceae, both negatively associated with mice’ weight gain and positively with
gut bacterial ClpB-like gene function.
Conclusions: In summary, gut bacterial ClpB-like gene function is associated with obesity status, a specific gut
microbiota composition and a plasma metabolomics profile in humans that could be partially transplanted to mice.
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Background
Obesity is rapidly becoming a global epidemic and its
management is a priority challenge to halting this ten-
dency. The role of the microbiota in the pathophysiology
of obesity [1] and related complications [2] is increas-
ingly recognized. The microbiota-gut-brain axis has been
associated with the regulation of metabolism, energy bal-
ance, adiposity, central appetite, and food reward [3, 4].
Gut microbiota could modulate intestinal satiety and
hunger hormones such as glucagon-like peptide-1 (GLP-
1), peptide YY (PYY), and ghrelin [5] that impact on an-
orexigenic and orexigenic pathways, and also proopiome-
lanocortin (POMC) and neuropeptide Y (NPY)/agouti-
related protein (AgRP) neurons, finally integrated in the
hypothalamus [6].
Host energy homeostasis could be regulated by the
bacterial production of metabolites and neurotransmit-
ters or even by energy harvesting of their own bacterial
metabolism [7, 8]. Recently, it has also been observed
that bacterial proteins which directly act in the brain via
vagal stimulation or indirectly through immune-
neuroendocrine mechanisms have an important role in
this process [7, 9]. One of these bacterial proteins, the
caseinolytic peptidase B protein homolog (ClpB), has
been identified as a conformational antigen-mimetic of
α-melanocyte-stimulating hormone (α-MSH) [10]. The
α-MSH is an amino-acid derived from POMC that acti-
vates the melanocortin-4 receptor (MC4R) expressed in
the hypothalamic paraventricular nucleus promoting the
anorexigenic pathway and therefore, regulating satiety,
energy, blood pressure, and growth [11].
Tennoune et al. found that ClpB-immunized mice pro-
duced anti-ClpB IgG cross-reactive with α-MSH, influ-
encing food intake and body weight. In addition, these
authors reported increased plasma levels of an antibody
anti-ClpB in patients with anorexia nervosa, bulimia,
and binge-eating disorder [10]. On the other hand,
Breton et al. described how regular nutrient provision
stabilized exponential growth of Escherichia coli, with
the stationary phase occurring 20min after nutrient sup-
ply [9]. ClpB was upregulated in the E. coli stationary
phase and plasma ClpB was proportional to ClpB DNA
in feces, stimulating the firing rate of hypothalamic
POMC neurons [9]. Furthermore, the administration of
a probiotic, Hafnia alvei, a ClpB-producing bacterium,
decreased fat mass and food intake in ob/ob and after
a high-fat diet in mice [12].
To our knowledge, there is little evidence assessing
ClpB gene function in subjects with obesity. Current in-
formation points to a lower gene richness in individuals
with obesity and a negative association with body mass
index of bacteria belonging to genera of Enterobacter,
Klebsiella, and Hafnia in sillico analysis using the Meta-
HIT database [12]. Therefore, our main aim was to
evaluate gut bacterial ClpB-like gene function in subjects
with obesity compared to controls and assess the poten-
tial role of the microbiota composition and microbial-
derived compounds in the modulation of body weight.
Results
Gut bacterial ClpB-like gene function is associated with
decreased body weight in humans
A consecutive series of 131 subjects, 76 of them with
obesity and their respective paired by sex and age con-
trols, was studied (Table 1). The detection of the gut
bacterial ClpB-like gene function assessed using shotgun
metagenomic analysis of fecal microbiota using the
KEGG annotation, K03695 (subcategory (sc): aging/pro-
tein families: genetic information processing; pathway
(p): longevity regulating pathway—multiple species
[PATH:ko04213]/chaperones and folding catalysts [BR:
ko03110]; annotation description (ad): ClpB ATP-
dependent Clp protease ATP-binding subunit ClpB; and
annotation (a): K03695). This function was significantly
lower in subjects with obesity (Fig. 1a; Table 1). In
addition, this ClpB-like gene function was negatively as-
sociated with body mass index (Fig. 1b), waist circumfer-
ence (Fig. 1c), and total fat mass (Fig. 1d). Other KEGG
functions were also negatively associated with body mass
index but not so strongly, such as K01358 (r = -0.277, p
= 0.001; sc: cell growth and death/aging/protein families:
metabolism; p: cell cycle—Caulobacter [PATH:
ko04112]/longevity regulating pathway—worm [PATH:
ko04212]/peptidases [BR:ko01002]; ad: ClpP, CLPP
ATP-dependent Clp protease, protease subunit [EC:
3.4.21.92]; a: K01358) and K01419 (r = − 0.276, p =
0.001, sc: protein families: metabolism; p: peptidases
[BR:ko01002]; ad: hslV, clpQ ATP-dependent HslUV
protease, peptidase subunit HslV [EC:3.4.25.2]; and a:
K01419).
As diet is a well-known modifier of bacterial ecosys-
tems, we explored which dietary components, by focus-
ing on macronutrients and fiber, were linked to gut
bacterial ClpB-like gene function (K03695). As a crude
measure, total energy intake was negatively associated
with ClpB-like gene function (r = − 0.189, p = 0.041).
After adjusting for total energy intake and body weight,
gut bacterial ClpB-like function was directly associated
with proteins (r = 0.200, p = 0.032), carbohydrates (r =
0.224, p = 0.015), lipids (r = 0.303, p = 0.001), and fiber
intake (r = 0.193, p = 0.037). Nevertheless, in multiple
linear regression models, with gut bacterial ClpB-like
gene function (K03695) as dependent variable and body
mass index, sex, age, total energy intake, and each
macronutrient or fiber, as independent variables, only
body mass index (e.g., model with proteins, β = − 0.345,
p = 4.3 × 10−4) remained significantly associated with
gut bacterial ClpB-like gene function.
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Gut bacterial ClpB-like gene function and microbiota
composition and metabolites
Gut bacterial ClpB-like gene function was found to be
associated with bacterial metabolites in feces and plasma
samples. To note, ClpB was positively associated with
hippuric acid (r = 0.398, p = 2.85 × 10−4) and 3-
indolepropionic acid (r = 0.259, p = 0.034) in plasma
and lupeol in feces (r = 0.242, p = 0.039) and negatively
with cholic acid in feces (r = − 0.317, p = 0.008) (Fig. 2a,
b) and a common gut microbiota ecosystem was simul-
taneously associated with these metabolites and ClpB-
like gene function (Fig. 2c).
The bacterial families with the highest number of
reads that contributed most to the ClpB-like gene func-
tion were the following: Clostridiaceae, Ruminococaceae,
Lachnospiraceae, uncultured and not assigned Firmi-
cutes, and uncultured Clostridiales within the Firmicutes
phylum and Prevotellaceae, Bacteroidaceae, and Rikenel-
laceae within Bacteroidetes phylum (Fig. 3a; Additional
file 1). Interestingly, while the relative abundance (RA)
of not assigned Firmicutes (Fig. 3b), Rikenellaceae (Fig.
3c), and Clostridiaceae (Fig. 3d) families were lower in
subjects with obesity, these families were also positively
associated with gut bacterial ClpB-like gene function
(not assigned Firmicutes (r = 0.405, FDR = 2.93 × 10−2),
Rikenellaceae (r = 0.217, FDR = 0.031), and
Clostridiaceae (r = 0.239, FDR = 0.017)). Importantly,
the associations between ClpB-like gene function and
some families Clostridiaceae (r = 0.352, p = 4.2 × 10−5),
Ruminococaceae (r = 0.284, p = 0.001), not assigned
Firmicutes (r = 0.523, p = 2.1 × 10−10), and un-
cultured Firmicutes (r = 0.367, p = 1.8 × 10−5)
remained significant even after adjusting for body
mass index.
Focusing on the α-MSH molecular mimicry, the
families that most contributed to the ClpB-like gene
function (Fig. 3a) and were also detected in relative
lower abundance in subjects with obesity (Fig. 3b–d),
such as not assigned Firmicutes, Rikenellaceae, and Clos-
tridiaceae showed 48,192 and 175 sequences with 100%
homology with α-MSH epitope of E. coli with a total
mean of identity of 82.13%, 92.25%, and 81.36%, respect-
ively (Additional files 2-3). Other families, that also have
an important contribution to ClpB-like gene function,
such as uncultured Clostridiales, Ruminococcaceae,
Lachnospiraceae, uncultured Firmicutes, Prevotellaceae,
uncultured Bacteria, and Bacteroidaceae (Fig. 3a) pre-
sented 1068, 766, 855, 265, 262, 149, and 431 sequences
with a total homology with motif in E. coli and a total
mean of identity of 89.04%, 85.04%, 88.28%, 86.44%,
95.78%, 90.01%, and 93.64%, respectively (Additional
files 2-3).
Table 1 Clinical characteristics of the human samples
Without obesity With obesity
(n = 55) (n = 76) p value
Females n (%) 37 (67.3) 52 (68.4) 0.519
Age (years) 53.7 [17.4] 48.6 [15.7] 0.188
BMI (kg/m2) 24.9 (2.5) 43.2 (6.8) < 0.001
Waist (cm) 89.7 (9.6) 126.2 (14.1) < 0.001
Fat total (%) 32.5 (7.5) 49.6 (5.6) < 0.001
Android fat (%) 32.6 (10.5) 56.5 (5.4) < 0.001
Gynoid fat mass (%) 37.5 [15.6] 50.6 [8.7] < 0.001
SBP (mmHg) 124.0 (16.1) 139.2 (19.3) < 0.001
DBP (mmHg) 71.1 (11.0) 78.0 (10.9) 0.001
Glucose (mg/dL) 95.0 [13.0] 96.0 [13.5] 0.284
HbA1c (%) 5.5 (0.3) 5.6 (0.3) 0.016
Cholesterol (mg/dL) 200.0 [48.0] 183.5 [57.0] 0.043
LDL-cholesterol (mg/dL) 119.0 [48.0] 112.0 [58.8] 0.634
HDL-cholesterol (mg/dL) 63.9 (17.5) 53.5 (12.0) 0.005
Triglycerides (mg/dL) 79.0 [39.0] 111.5 [75.0] < 0.001
hsCRP (mg/dL) 0.7 [0.9] 4.9 [7.2] < 0.001
K03695 (AU) 1.6 × 10−1 (3.0 × 10−2) 1.4 × 10−1 (2.4 × 10−2) 8.0 × 10−6
Results are expressed as number and frequencies for categorical variables, mean and standard deviation (SD) for normal distributed continuous variables, and
median and interquartile range [IQR] for non-normal distributed continuous variables. To determine differences between study groups, we used χ2 for categorical
variables, unpaired Student’s t test in normal quantitative, and Mann-Whitney U test for non-normal quantitative variables. BMI body mass index, SBP systolic
blood pressure, DBP diastolic blood pressure, HbA1c glycated hemoglobin, LDL low density lipoprotein, HDL high density lipoprotein, hsCRP high-sensitive
C-reactive protein, AU arbitrary units
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Furthermore, the bacterial families whose reads more
contributed to the ClpB-like gene function were also as-
sociated with some bacterial metabolites (Fig. 2c).
Remarkably, a cluster of metabolites and not assigned
Firmicutes, Rikenellaceae, and Clostridiaceae, among
others, were identified (Fig. 2c).
Gut microbiota transplantation in mice
Finally, we tested the gut bacterial ClpB-like gene func-
tion in 33 mice with no significant differences in initial
body weight (Fig. 3e). After antibiotic treatment, 11 mice
were orally gavaged with vehicle and 22 with fecal ma-
terial from 22 subjects paired in age and sex. ClpB-like
gene function in mice showed a trend to be negatively
associated with body weight gain as the time of the ex-
periment passed (Fig. 3f) and also a negative tendency to
be associated with percent weight gain at the end of the
experiment (Fig. 3g). ClpB-like gene function in humans
was not significantly associated with ClpB-like gene
function in mice. Nevertheless, the families that more
contributed to ClpB-like gene function in humans were
also associated with ClpB-like gene function in mice
after adjusting for the donor’s body mass index, such as
not assigned Firmicutes (r = 0.621, p = 0.003),
uncultured Firmicutes (r = 0.529, p = 0.014), Prevotella-
ceae (r = 0.725, p = 4.1 × 10−7), Rikenellaceae (r = 0.702,
p = 3.9 × 10−4), and Ruminococcaceae (r = 0.526, p =
0.014). Furthermore, two of the bacterial families that
more contributed to the gut bacterial ClpB-like function
in humans, Clostridiaceae (r = − 0.445, p = 0.038) and
Prevotellaceae (r = − 0.479, p = 0.024) were negatively
associated with weight gain in mice (Fig. 3h). The abso-
lute abundance (AA) of Prevotellaceae in mice was also
positively associated with the gut bacterial ClpB-like
gene function in mice (Fig. 3i). A deeper analysis using
DESeq2 [13] identified species of Prevotellaceae, both
negatively associated with mice’ weight in the 7th week
of follow-up (Fig. 3j) and positively with gut bacterial
ClpB-like gene function (Fig. 3k).
Discussion
Gut bacterial ClpB-like gene function in feces (KEGG
annotation: K03695) was associated with decreased body
weight, central obesity, and total fat mass in humans.
Accordingly, this gut bacterial function was found in
lower relative abundance in subjects with obesity. These
results are in line with previous evidence in mouse
models and in sillico findings. In a recent study, the
Fig. 1 Gut bacterial ClpB-like gene function is associated with decreased body weight in humans. a Box plot showing the differences of gut
bacterial ClpB-like gene function (K03695, KEGG annotation) between subjects without (body mass index, BMI 18.5–30 kg/m2) and with obesity
(BMI ≥ 30 kg/m2). b Scatterplot displaying the relationship between BMI and gut bacterial ClpB-like gene function. c Scatterplot of the
relationship between waist circumference and gut bacterial ClpB-like gene function. d Scatterplot of the relationship between the percentage of
total fat mass assessed by DEXA and gut bacterial ClpB-like gene function
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administration of a probiotic, Hafnia alvei, a ClpB-
producing bacterium reduced fat mass and food intake
in ob/ob and after a high-fat diet in mice [12] and also
improved their metabolic profile [14]. In this study, the
enterobacterial ClpB gene was also tested in sillico ana-
lysis of fecal metagenomes from the MetaHIT database
[12]. To our knowledge, our study sets up the first evi-
dence of the association of ClpB gene function and obes-
ity in a clinical setting.
The caseinolytic protease B (ClpB) protein described
in E. coli is an ATP-dependent ring forming chaperone
that mediates the resolubilization of aggregated proteins
[15]. This gut bacteria ClpB protein has been identified
as a conformational antigen-mimetic of α-MSH that
could activate the MC4R in the hypothalamus ultimately
promoting the anorexigenic pathway [10]. In that sense,
autoantibodies that interreacted with the α-MSH were
found elevated in subjects with anorexia and bulimia
nervosa [16, 17], and plasma levels of ClpB were
proportional to ClpB DNA in feces [9]. In our study,
metagenomic analysis of fecal microbiota revealed that
the RA of Rikenellaceae, Clostridiaceae and not assigned
Firmicutes were positively associated with ClpB gene
function and were detected in lower relative abundance
in subjects with obesity. Tennoune et al. firstly demon-
strated the α-MSH mimetic ClpB protein in E. coli from
the phylum Proteobacteria [10]. Other sources of α-
MSH-like epitope of E.coli ClpB identified in sillico ana-
lysis were bacteria belonging to the genera Escherichia,
Salmonella, Shigella, Klebsiella, Enterobacter, Citrobac-
ter, Cronobacter, and Hafnia, and in that search, the
ClpB appeared to be specific to the family Enterobacteri-
aceae and in some Brassicaceae [18]. However, except
for E. coli ClpB, we did not find studies that have tested
the properties of this protein in the previous genera de-
scribed. Other bacteria that present sequence homology
in at least five amino acids with α-MSH have been re-
ported, such as bacteria belonging to the phyla
Fig. 2 Gut bacterial ClpB-like gene function and microbiota metabolites. a Significant O-PLS correlations coefficients for the model between gut
bacterial ClpB-like gene function (K03695, KEGG annotation) and metabolites in feces (data in feces was previously normalized using the
probabilistic quotient normalization (PQN)). b Significant O-PLS correlation coefficients for the model between gut bacterial ClpB-like gene
function (K03695, KEGG annotation) and metabolites in plasma. c Heatmap showing the Spearman correlation coefficients and associated p
values adjusting by FDR between significant metabolites in plasma and feces and bacterial families. Hierarchical clustering analysis was performed
using Ward linkage and Euclidean distance. A cluster with the strongest correlations is highlighted with a black square
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Bacteroidetes, Actinobacteria (Bifidobacterium longum,
Frankia), Firmicutes (Bacillus cereus, Clostridium
tetani), or Proteobacteria (Helicobacter) [19]. In our
study, we have identified that the sequences of the bac-
terial families which more contributed to gut bacterial
ClpB-like gene function presented the motif of α-MSH-
like epitope of E.coli ClpB, suggesting that this mechan-
ism could be shared with other bacterial families and
might be explain the role on body weight regulation.
However, the presence of amino-acid sequence hom-
ology does not imply the same molecular function and
experimental studies are needed to test the α-MSH
mimicry of the different ClpB proteins from other mi-
crobial organisms [18]. Nonetheless, there is some evi-
dence that gut bacterial ClpB-like gene function, either
by the same α-MSH-like epitope of ClpB E.coli with an
effect on the anorexigenic pathway [18] or by others
ClpB fragments with other unknown routes implicated,
seems to have a role in the pathophysiology of obesity
attributed to the gut microbiota.
In addition, we found a relationship between the diet
and the detection of ClpB-like gene function in humans.
In general, a negative association was found between
total energy intake and gut bacterial ClpB-like gene
function. This data is concordant with previous evidence
in mice in which the dietary restriction induced an in-
crease of ClpB [20]. On the contrary, we observed posi-
tive associations between ClpB-like gene function and
different macronutrients and fiber. Proteins have been
identified as the main contributors to the ClpB E.coli
Fig. 3 Gut bacterial ClpB-like gene function and metagenomics. a Top bacterial taxa at the family level contributing reads to the gut bacterial
ClpB-like gene function, in total relative figures per sample (uncultured, uc; not assigned, na). b–d Box plots showing the differences of some of
the top ten bacterial families (relative abundance, RA) contributing to the gut bacterial ClpB-like gene function in subjects with and without
obesity. e Mice body weights after gut microbiota transplantation. Controls (mouse, M; control, c) are shown in yellow (n = 11) and mice which
received microbiota from human donors (transplant, t) are shown in blue (n = 22). f Bar chart showing mean and standard deviation mice body
weights, regarding the median of the gut bacterial ClpB-like gene function detected in mice, K03695 (arbitrary units, AU). g Scatterplot showing
the relationship between percent weight gain in mice (calculated as (body weight final (g)—body weight initial (g))/body weight initial (g)*100)
and gut bacterial ClpB-like gene function, K03695 (AU), in mice. h Scatterplot showing the relationship between percent weight gain in mice and
Prevotellaceae RA in humans. i Scatterplot showing the relationship between gut bacterial ClpB-like gene function (K03695, KEGG annotation) and
Prevotellaceae absolute abundance (AA) in mice. j Scatterplot showing the relationship between the final weight (7th week) in mice and
Prevotellaceae baroniae AA in humans. k Scatterplot showing the relationship between gut bacterial ClpB-like gene function (K03695, KEGG
annotation) in mice and Prevotellaceae baroniae AA in human donors
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levels in in vitro studies [21]. In our study, positive rela-
tionships were found not only with total protein intake
but also with fiber intake and the rest of macronutrients.
However, the strength of the body mass index appeared
to be more important than the role of each macronutri-
ent separately. Interestingly, ClpB-like gene function was
associated with some metabolites in plasma such as hip-
puric acid and 3-indolepropionic acid, or lupeol and
cholic acid in feces. The direction of the relationships is
in line with current evidence. Higher levels of hippuric
acid have been associated with a beneficial metabolic
profile, decreased fasting plasma glucose and insulin se-
cretion [22]. Similar observations have been made regard-
ing 3-indolepropionic acid [23]. Lupeol has exhibited
antioxidant, anti-inflammatory, anti-hyperglycemic,
hypolipemiant, and anti-mutagenic properties [24].
In the animal experiment, microbial families that seem
to contribute to the gut bacterial ClpB-like gene func-
tion, such as Prevotellaceae and Clostridiaceae were
negatively associated with weight gain during the 7
weeks of follow-up. Despite not directly observing a
negative significant association between gut bacterial
ClpB-like gene function and weight gain in mice, it can
be seen a tendency as the time of the experiment passed.
Maybe, if the duration of the study would have been lon-
ger or the mice sample size larger, a significant associ-
ation would be reached. In any case, the direction of the
association between gut bacterial ClpB-like gene func-
tion and body weight seems to be shared between
humans and mice. This would be the first study investi-
gating the effects of microbiota transplantation from
humans to mice evaluating ClpB function. Previous re-
ports in mice were based on chronic intragastric delivery
of E.coli [10] and H. alvei [12].
Conclusions
ClpB protein has been previously studied in animal
models [9, 10]. Antibody anti-ClpB was investigated in a
single human study [10]. This is the first study, to our
knowledge, evaluating gut bacterial ClpB-like gene function
in human subjects linked to obesity status, gut bacterial
ecosystem, and diet. The findings of the current study show
that a bacterial ecosystem enriched in ClpB-like gene func-
tion that was negatively associated with body mass index,
waist circumference, and fat mass, and detected in lower
abundance in subjects with obesity. We speculate that this
gut bacterial ClpB-like function could lead to increased sati-
ety and decreased fat mass in the long term.
Methods
Clinical study
Recruitment of study subjects
From January 2016 to October 2017, a cross-sectional
case-control study was undertaken in the Endocrinology
Department of Josep Trueta University Hospital. We in-
cluded consecutive subjects with obesity (body mass
index, BMI ≥ 30 kg/m2) and age- and sex-matched non-
obese subjects (BMI 18.5–30 kg/m2), with an age range
of 27.2–66.6 years. Exclusion criteria were: type 2 dia-
betes mellitus, chronic inflammatory systemic diseases,
acute, or chronic infections in the previous month; use
of antibiotic, antifungal, antiviral, or treatment with
proton-pump inhibitors; severe disorders of eating be-
havior or major psychiatric antecedents; or excessive al-
cohol intake (≥ 40gOH/day in women or 80gOH/day in
men). The institutional review board—Ethics Committee
and the Committee for Clinical Research (CEIC) of Dr.
Josep Trueta University Hospital (Girona, Spain)—ap-
proved the study protocol and informed written consent
was obtained from all participants.
Clinical and laboratory parameters
Body composition was assessed using a dual energy
x-ray absorptiometry (DEXA, GE lunar, Madison,
Wisconsin).
Dietary pattern
The dietary characteristics of the subjects were collected
in a personal interview using a validated food-frequency
questionnaire [25].
Extraction of fecal genomic DNA and whole-genome
shotgun sequencing
Total DNA was extracted from frozen human stools
using the QIAamp DNA mini stool kit (Qiagen, Courta-
boeuf, France). Quantification of DNA was performed
with a Qubit 3.0 fluorometer (Thermo Fisher Scientific,
Carlsbad, CA, USA), and 1 ng of each sample (0.2 ng/μL)
was used for shot gun library preparation for high-
throughput sequencing, using the Nextera DNA Flex
Library Prep kit (Illumina, Inc., San Diego, CA, USA)
according to the manufacturers’ protocol. Sequencing
was carried out on a NextSeq 500 sequencing system
(Illumina) with 2 × 150-bp paired-end chemistry, at the
facilities of the Sequencing and Bioinformatic Service of
the FISABIO (Valencia, Spain).
The obtained input fastq files were decompressed, fil-
tered, and 3 ends-trimmed by quality, using prinseq-lite-
0.20.4 program [26] and overlapping pairs were joined
using FLASH-1.2.11 [27]. Fastq files were then converted
into fast files, and human and mouse host reads were re-
moved by mapping the reads against the GRCh38.p11,
reference human genome (Dec 2013), and GRCm38.p6,
reference mouse genome (Sept 2017), respectively, by
using bowtie2-2.3.4.3 [28] with end-to-end and very
sensitive options.
Next, functional analyses were carried out by assem-
bling the non-host reads into contigs by MEGAHIT
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v1.1.2 [29] and mapping those reads against the contigs
with bowtie 2. Reads that did not assemble were
appended to the contigs. Next, the program Prodigal
v2.6.342 [30] was used for predicting codifying regions.
Functional annotation was carried out with HMMER
[31] against the Kyoto Encyclopedia of Genes and Ge-
nomes (KEGG) database, version 2016 [32] to obtain the
functional subcategory, route, and annotation of the
genes. An in-house pipeline, consisting of a series of
consecutive customized scripts, implemented by the stat-
istical package R 3.1.0 [33], coordinated and
concatenated by shell commands, was applied to the
functionally annotated reads to first parse the HMMER
table, and next to get the best annotation per open read-
ing frame (ORF) and to identify which ORFs were anno-
tated, followed by getting the nucleotides and amino
acids sequences. Next, it allowed us to get non-singleton
contigs with annotated ORFs (annotated contigs), add
the annotation for each ORF, get the reads inside that
annotated ORFs, count the alignments per annotation,
count alignment per category (a specific annotation can
belong to multiple categories), and finally build a contin-
gency table to which descriptions were added.
Taxonomic annotation was implemented with Kaiju
v1.6.2 [34] on the human and mouse-free reads.
Addition of lineage information was added, counting of
taxa and generation of an abundance matrix for all sam-
ples were performed using the package R.
Molecular mimicry
The mimetic amino acid motif of the α-MSH peptide
(RWGKPV) was first aligned to the ClpB from E. coli str
K12 (accession number NP_417083.1). Then, the pre-
dicted ORFs from each sequence were aligned with
Clustal Omega [35] to the previous two sequences.
Those that encompassed the region that contained the
epitope-like sequence were filtered, discarding reads
which not included it. Sequences beyond 30 amino acids
before and after the aligned α-MSH peptide were
trimmed and 40 alignments were plotted. R scripts [33]
allowed us to create a table with the aligned motif and
calculate the identity between the E. coli and the micro-
bial counterparts in the sequences, as well as, assign the
taxonomy, at family level, to each contig or single read.
The average identity of the epitope in each bacterial
family compared to the motif in E. coli as well as the dis-
tribution of families through the sequences according to
their degree of homology were also calculated with R
package [33].
Metabolomics analyses
For non-targeted metabolomics analysis, metabolites
were extracted from fecal samples with methanol ac-
cording to previously described methods [36], by using
phenylalanine-C13 as internal standard. After 1 h at −
20 °C, methanol supernatants were centrifuged at 12000g
for 3 min and evaporated using a Speed Vac (Thermo
Fisher Scientific, Barcelona, Spain). The resulting pellets
were resuspended in water with 0.4% acetic acid/metha-
nol (50/50).
We used an ultra-high-pressure liquid chromatog-
raphy (UHPLC) with an Agilent 1290 LC system
coupled to an electrospray-ionization quadruple time
of flight mass spectrometer (Q-TOF) 6520 instrument
(Agilent Technologies, Barcelona, Spain). A column
with 1.8 μm particle size was employed and we per-
formed the preliminary identification of differential
metabolites by using the database PCDL from Agilent
(Agilent Technologies, Barcelona, Spain), which uses
retention times, exact mass, and isotope distribution
in a standardized chromatographic system as an or-
thogonal searchable parameter to complement accu-
rate mass data (AMRT approach) according to
previously published works [37].
Animal procedures
Male C57BL/6 J mice (Charles River, France), weighing
29–26 g at the beginning of the experiment were used in
this study. Mice were housed individually in controlled
laboratory conditions with the temperature maintained
at 21 ± 1 °C and humidity at 55 ± 10% during all the
study. Animal procedures were conducted in strict ac-
cordance with the guidelines of the European Communi-
ties Directive 86/609/EEC regulating animal research
and were approved by the local ethical committee
(CEEA-PRBB). All the experiments were performed
under blinded conditions.
Then, mice were given a cocktail of ampicillin and
metronidazole, vancomycin (all at 500 mg/L), cipro-
floxacin HCl (200 mg/L), and imipenem (250 mg/L)
once daily for 14 consecutive days in drinking water,
as previously described [38]. Seventy-two hours later,
animals were colonized via daily oral gavage of donor
microbiota (150 μL) for 3 days. Animals were orally
gavaged with fecal material from healthy volunteers
(n = 22). To offset potential confounder and/or cage
effects and to reinforce the donor microbiota pheno-
type, booster inoculations were given twice per week
throughout the study. Animals were maintained on
normal mouse chow diet (Rat and Mouse No. 1
Maintenance Diet, Special Diet Services, Essex, UK)
and water ad libitum, and were weighted every week
during 7 weeks. Food intake was the same in the two
groups. At the end of the study, the animals were
consecutively sacrificed. The cecum was removed,
weighted, and stored, and the feces collected and
stored at − 80 °C for microbiota analysis.
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Statistical analysis
Firstly, normal distribution and homogeneity of vari-
ances were tested. Results are expressed as number and
frequencies for categorical variables, mean and standard
deviation (SD) for normal distributed continuous vari-
ables, and median and interquartile range [IQR] for non-
normal distributed continuous variables. To determine
differences between study groups, we used χ2 for cat-
egorical variables, unpaired Student’s t test in normal
quantitative, and Mann-Whitney U test for non-normal
quantitative variables. Nonparametric Spearman analysis
was used to determine the correlation between quantita-
tive variables. These analyses were performed using
SPSS version 24 (IBM Corp., Armonk, NY) and Graph-
Pad Prism version 8.00 (GraphPad Software, La Jolla,
CA, USA).
Metabolomics data were analyzed using in-house
MATLAB scripts. Orthogonal projection to latent struc-
tures (O-PLS) using unit variance scaling was then ap-
plied to identify metabolites associated with the gut
bacterial ClpB-like gene function. Metabolites were used
as the descriptor matrices (X) and gut bacterial ClpB-
like gene function was used as the response (Y). The
predictive performance (Q2Y) of each model was calcu-
lated using a seven-fold cross-validation approach and
model validity was established by permutation testing
(1000 permutations). Significance of O-PLS correlation
coefficients was adjusted by the Benjamini-Hochberg
method (FDR) [39].
Bacterial taxa associated with the gut bacterial ClpB-
like gene function in humans were identified using the
DESeq2 R packages [13]. Taxa were previously filtered
so that only those with more than 10 reads in at least
two samples were selected.
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